SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc. (Amendment)

$YMAB
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $YMAB alert in real time by email
SC 13G/A 1 tm245871d4_sc13ga.htm SC 13G/A

 

 

 

  UNITED STATES  
  SECURITIES AND EXCHANGE COMMISSION  
  Washington, D.C. 20549  

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No. 6)*

 

Y-mAbs Therapeutics, Inc.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

984241109

(CUSIP Number)

 

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  ¨ Rule 13d-1(b)
     
  x Rule 13d-1(c)
     
  ¨ Rule 13d-1(d)

 

*            The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

  1. Name of Reporting Persons:
HBM Healthcare Investments (Cayman) Ltd.
  2. Check the Appropriate Box if a Member of a Group
    (a) ¨
    (b) ¨
  3. SEC Use Only
  4. Citizenship or Place of Organization:
Cayman Islands, British West Indies

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
  5. Sole Voting Power:
3,297,800
  6. Shared Voting Power:
0
  7. Sole Dispositive Power:
3,297,800
  8. Shared Dispositive Power:
0

  9. Aggregate Amount Beneficially Owned by Each Reporting Person:
3,297,800
  10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
  11. Percent of Class Represented by Amount in Row (9):
7.6% (1)
  12. Type of Reporting Person (See Instructions):
CO

 

(1)Based on 43,621,618 shares of the Issuer’s Common Stock outstanding as of November 6, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2023.

 

 

 

 

Item 1. (a). Name of Issuer:
Y-mAbs Therapeutics, Inc.
  (b).

Address of Issuer’s Principal Executive Offices:
230 Park Avenue

Suite 3350

New York, New York 10169

Item 2(a).  

Name of Person Filing:

HBM Healthcare Investments (Cayman) Ltd.

Item 2(b).  

Address of Principal Business Office:

Governors Square

23 Lime Tree Bay Avenue

PO Box 30852

Grand Cayman, Cayman Islands

Item 2(c).  

Citizenship:

Cayman Islands, British West Indies

Item 2(d).   Title of Class of Securities:
Common Stock, $0.0001 par value

Item 2(e).   CUSIP Number:
984241109
Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
  Not Applicable.
Item 4. Ownership.
  (a)

Amount beneficially owned:

3,297,800 (1)

  (b)

Percent of class:

7.6% (2)

  (c)

Number of shares as to which the Reporting Person has:

 

    (i)

Sole power to vote or to direct the vote:

3,297,800 (1)

    (ii)

Shared power to vote or to direct the vote:

0

    (iii)

Sole power to dispose or to direct the disposition of:

3,297,800 (1)

    (iv)

Shared power to dispose or to direct the disposition of:

0

 

 

 

 

Item 5. Ownership of Five Percent or Less of a Class
  Not Applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
  Not Applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
  Not Applicable.
Item 8. Identification and Classification of Members of the Group.
  Not Applicable.
Item 9. Notice of Dissolution of Group.
  Not Applicable.
Item 10. Certification.
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
  (1) Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd. (the “Board”). The Board consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D. and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares.
  (2) Based on 43,621,618 shares of the Issuer’s Common Stock outstanding as of November 6, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2023.

 

 

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 13, 2024

 

  HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD.  
   
  By: /s/ Jean-Marc LeSieur
  Name: Jean-Marc LeSieur
  Title: Managing Director

 

SIGNATURE PAGE TO SCHEDULE 13G AMENDMENT NO. 6 (Y-MABS THERAPEUTICS, INC.)

 

 

 

Get the next $YMAB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$YMAB

DatePrice TargetRatingAnalyst
11/18/2024$23.00Outperform
Oppenheimer
8/16/2024$20.00Overweight
Cantor Fitzgerald
6/28/2024$21.00Buy
Truist
5/10/2023$5.00 → $13.00Neutral → Outperform
Wedbush
4/3/2023Buy → Neutral
Guggenheim
1/27/2023$4.00Equal-Weight → Underweight
Morgan Stanley
1/5/2023Outperform → Market Perform
Cowen
12/2/2022$23.00 → $5.00Buy → Neutral
BofA Securities
More analyst ratings

$YMAB
Press Releases

Fastest customizable press release news feed in the world

See more
  • Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

    Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

    NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with relapsed/refractory high-risk neuroblastoma in the journal Nature Communications. The article, titled "The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

    NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$YMAB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$YMAB
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$YMAB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$YMAB
SEC Filings

See more

$YMAB
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

    Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$YMAB
Leadership Updates

Live Leadership Updates

See more
  • Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

    NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. "I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head," said Michael Rossi, President and Chief Executive Officer. "We believe Doug's extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our co

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

    NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

    NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. "We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in develop

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$YMAB
Financials

Live finance-specific insights

See more
  • Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

    Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

    NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

    Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024Achieved extension of primary DANYELZA U.S. patent through February 2034Continued geographic expansion of DANYELZA with new market revenues recorded in the third quarter from TurkeyManagement reiterates Full Year 2024 guidance around Total Net Revenue, Operating Expenses, and Cash Flow Investment The Company will host a conference call on Friday, November 8, 2024, at 8:00 a.m. ET NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-

    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$YMAB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more